The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Alendronate Treatment in Women With Normal to Severely Impaired Renal Function: An Analysis of the Fracture Intervention Trial
Abstract
To determine if alendronate had differential effects on BMD and fracture by renal function, we performed a secondary data analysis of women participating in the FIT. Alendronate increased BMD and decreased fractures to a similar degree among women with and without reduced renal function. There was no increase in adverse events among women with impaired renal function treated with alendronate. Alendronate is safe and effective among this group of women with reduced renal function. Introduction: Alendronate is cleared by the kidney and may have sustained effects on bone in subjects with impaired renal function. We hypothesized that, with decreasing renal function, alendronate treatment would result in greater increases in BMD and greater decreases in fractures and that the frequency of adverse events would be increased. Materials and Methods: We studied women participating in the Fracture Intervention Trial (FIT), a randomized controlled trial of alendronate or placebo (n = 6458). We estimated baseline creatinine clearance (eGFR) using the Cockcroft Gault Formula. Results: Five hundred eighty-one (9.9%) participants had a severely reduced eGFR (<45 ml/minute). Alendronate increased BMD regardless of eGFR, but women with reduced eGFR had a 5.6% (95% CI: 4.8–6.5) increase in total hip BMD compared with 4.8% (95% CI: 4.6–5.0) among women with normal to moderate renal dysfunction (interaction: p = 0.04). Compared with placebo, alendronate increased spine BMD by 6.6 ± 5.8%, but there was no significant interaction for the increase in spine BMD (interaction: p = 0.75). Treatment with alendronate reduced the risk of clinical fractures to a similar degree in those with (OR: 0.78; 95% CI: 0.51–1.21) and without reduced renal function (OR: 0.80; 95% CI; 0.70–0.93; p for interaction = 0.89). Treatment with alendronate reduced the risk of spine fractures to a similar degree in those with (OR: 0.72; 95% CI: 0.31–1.7) and without reduced renal function (OR: 0.50; 95% CI: 0.32–0.76; p for interaction = 0.44). There were no differences in adverse events by renal function. Conclusions: Alendronate is safe and effective at increasing BMD and decreasing fractures among this group of women with reduced renal function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
Massry, S. G., Coburn, J. W., Chertow, G. M., Hruska, K. A., Langman, C. B., Malluche, H. H., Martin, K. J., McCann, L. M., McCarthy, J. T., Moe, S. M., et al. (2003) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 2,527
Longitudinal Studies on the Rate of Decline in Renal Function with Age
Lindeman, R. D., Tobin, J., & Shock, N. W. (1985) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1985.tb07117.x · Cited by 1,578
Goodpasture syndrome during the course of a Schönlein-Henoch purpura
Carreras, L., Poveda, R., Bas, J., Mestre, M., Rama, I., & Carrera, M. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32799 · Cited by 1,474
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black, D. M., Thompson, D. E., Bauer, D. C., Ensrud, K., Musliner, T., Hochberg, M. C., Nevitt, M. C., Suryawanshi, S., & Cummings, S. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6953 · Cited by 982
Self-citationBisphosphonates: A review of their pharmacokinetic properties
Lin, J. H. (1996) · Bone · doi:10.1016/8756-3282(95)00445-9 · Cited by 932
Increased risk of hip fracture among patients with end-stage renal disease
Alem, A. M., Sherrard, D. J., Gillen, D. L., Weiss, N. S., Beresford, S. A., Heckbert, S. R., Wong, C., & Stehman-Breen, C. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00178.x · Cited by 883
Clinical Use of Bone Densitometry: Scientific Review
Cummings, S. R., Bates, D., & Black, D. M. (2002) · JAMA · doi:10.1001/jama.288.15.1889 · Cited by 817
Self-citationFroissart, M., Rossert, J., Jacquot, C., Paillard, M., & Houillier, P. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004070549 · Cited by 803
Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone
Coco, M., & Rush, H. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.19812 · Cited by 603
Miller, P. D., Roux, C., Boonen, S., Barton, I. P., Dunlap, L. E., & Burgio, D. E. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050817 · Cited by 318
Vervoort, G. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.11.1909 · Cited by 243
Upper Gastrointestinal Tract Safety Profile of Alendronate: The Fracture Intervention Trial
Bauer, D. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.517 · Cited by 215
Self-citationRelationship between age, renal function and bone mineral density in the US population
Klawansky, S., Komaroff, E., Cavanaugh, P. F., Mitchell, D. Y., Gordon, M. J., Connelly, J. E., & Ross, S. D. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1435-y · Cited by 196
Boonen, S., McClung, M. R., Eastell, R., El‐Hajj Fuleihan, G., Barton, I. P., & Delmas, P. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52506.x · Cited by 179
Assessment of prevalent and incident vertebral fractures in osteoporosis research
Genant, H. K., & Jergas, M. (2003) · Osteoporosis International · doi:10.1007/s00198-002-1348-1 · Cited by 178
Design of the Fracture Intervention Trial
Black, D. M., Reiss, T. R., Nevitt, M. C., Cauley, J., Karpf, D., Cummings, S. R., & the Fracture Intervention Trial Research Group (1993) · Osteoporosis International · doi:10.1007/bf01623005 · Cited by 174
Self-citationLong-Term Precision of DXA Scanning Assessed over Seven Years in Forty Postmenopausal Women
Patel, R., Blake, G. M., RYMER, J. M., & Fogelman, I. (2000) · Osteoporosis International · doi:10.1007/s001980050008 · Cited by 115
Renal secretion of diphosphonates in rats
Tröhler, U., Bonjour, J., & Fleisch, H. A. (1975) · Kidney International · doi:10.1038/ki.1975.70 · Cited by 85
Clinical utility of laboratory testing in women with osteoporosis
Jamal, S. A., Leiter, R. E., Bayoumi, A. M., Bauer, D. C., & Cummings, S. R. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1718-y · Cited by 81
Self-citationRegulation of skeletal remodeling by biomechanical input
Rubin, J. E. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1472-6 · Cited by 21
Assessment of oral bisphosphonate use in elderly patients with varying degrees of kidney function
Linnebur, S. A., & Milchak, J. L. (2004) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2004.10.001 · Cited by 13
Cited by
(2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.04.001 · Cited by 1,956
Denosumab and bisphosphonates: Different mechanisms of action and effects
Baron, R., Ferrari, S., & Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2010.11.020 · Cited by 715
Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676
Long-Term Use of Bisphosphonates in Osteoporosis
Watts, N. B., & Diab, D. L. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1947 · Cited by 542
MacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M., Mojica, W., Timmer, M., Alexander, A., McNamara, M., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-3-200802050-00198 · Cited by 529
Metadata
- Authors
- Jamal, S. A., Bauer, D. C., Ensrud, K. E., Cauley, J. A., Hochberg, M., Ishani, A., & Cummings, S. R.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-04-01
- Volume
- 22
- Issue
- 4
- Pages
- 503-508
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2085739273
- Cited by
- 301
- References
- 23
- FWCI
- 18.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.